Global Intravenous Solution Market, by Solution (Saline (Normal Saline (0.9% NaCl) and Hypertonic Saline), Dextran, Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and Trace Elements, and Mixed Solutions), by Bag Type (Large Volume Bags (greater than 250ml) and Small Volume Bags (less than 250ml)), by Application (Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, and Irrigation IV Solution), by End User (Hospitals, Clinics, Ambulatory Surgery Centers, and Home Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  9,907.8 Million in 2022 and is projected to exhibit a CAGR of 6.1% over the forecast period (2022– 2030).

Increasing cases of kidney failures are expected to lead to high adoption of dialysis procedures, which is expected to drive the market growth over the forecast period. Kidney failure is a condition in which the kidney loses its functioning ability of removing waste and extra fluids from the body. Dialysis procedure is recommended for such conditions. For instance, according to the National Kidney Foundation Factsheet, in March 2021, approximately 90% of those with kidney disease were unidentified by the people in U.S. and approximately 80 million people in U.S were at risk for kidney disease.

 Moreover, in December 2021, Centers for Disease Control and Prevention’s, a national public health agency of the U.S., published a report which reported that in 2019, 15% of the U.S. adults or 37 Million people, are estimated to have CKD (chronic kidney disease). CKD is more common in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%).

Global Intravenous Solution Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.

Increasing number of COVID patient lead to greater no of hospital admission particularly due to severe lung infections which lead to increase in demand of intravenous solutions. For instance, in May 2020, the World Health Organization, published a report on Clinical Management of Covid-19, which recommended that Patients with COVID-19 should be treated cautiously with intravenous fluids as aggressive fluid resuscitation may worsen oxygenation, especially in settings where there is limited availability of mechanical ventilation. 

Thus, impact of the Coronavirus (COVID-19) pandemic has driven growth of the global intravenous solutions market during the forecast period.   

Global Intravenous Solution Market: Key Developments

Increasing collaborations, launch and acquisitions among key players to develop new intravenous product is expected to drive growth of the Global Intravenous Solutions market. For instance, on January 6, 2022, ICU Medical Inc., a medical devices company, announced the acquisition of Smiths Medical from Smiths Group plc, an engineering business company. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies will be an infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion.

For instance, in June 2019, Eurolife Healthcare, manufacturing and distributioncompany of specialty infusion & pharmaceuticals, launched the high quality Intravenous IV products name Discport and Lifeport in the Indian drug market. Positioned as smart intravenous infusion, both products encompass the latest technology that reduce the chances of any infections apart from ease of use.

Browse 34 Market Data Tables and 30 Figures spread through 215 Pages and in-depth TOC on "Intravenous Solution Market, by Solution (Saline (Normal Saline (0.9% NaCl) and Hypertonic Saline), Dextran, Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and Trace Elements, and Mixed Solutions), by Bag Type (Large Volume Bags (greater than 250ml) and Small Volume Bags (less than 250ml)), by Application (Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, and Irrigation IV Solution), by End User (Hospitals, Clinics, Ambulatory Surgery Centers and, Home Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global Forecast to 2030”

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/intravenous-solutions-market-1134

Moreover, in June 2020, The U.S. Food and Drug Administration (FDA) approved Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's , a pharmaceutical company, new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the blood stream and reduce A1C levels. As a rapid-acting mealtime insulin, Lyumjev controls high blood sugar levels after meals in adults with diabetes, similar to how natural insulin works after meals in people without diabetes.

Key Takeaways of the Global Intravenous Solution Market:

  • Global intravenous solution market is expected to witness a CAGR of 6.1 % during the forecast period, owing to increasing cases of kidney diseases.
  • Among solution type, saline segment is expected to account for major revenue share in 2030, owing to increasing incidence of gastroenteritis globally. For instance, in March 2021, according to the Center of Disease Control and Prevention, national public health agency of the U.S., about 200 million cases were seen among children under 5 years old, leading to an estimated 50,000 child deaths every year in the U.S.
  • Among application, basic IV segment is expected to hold a dominant position in market over the forecast period, owing to increasing new launch by the key market players. For instance, in September 2021, B. Braun Medical Inc., an infusion therapy and pain management company, announced the launch of its new CARESAFE IV Administration sets with optional Airstop component. CARESAFE IV Sets are the robust portfolio of IV administration sets in the U.S. market that are not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP). They provide an added level of protection for the environment and, most importantly, to patients from the potential health risks associated with exposure to these chemicals.
  • Among distribution channel, hospital pharmacies segment is expected to hold dominant position over the forecast period as reimbursement and pricing of drugs are more favorable in hospital pharmacies, owing to 340B pricing program( Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients)
  • Key players operating in the global Intravenous Solutions market include, Baxter International Inc. ICU Medical, Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo